ISTA Pharmaceuticals (Products now under Bausch + Lomb, which was acquired by Valeant) Revenue
Pharmaceutical Manufacturing • 
Irvine, California, United States • 101-200 Employees
ISTA Pharmaceuticals (Products now under Bausch + Lomb, which was acquired by Valeant) revenue & valuation
| Annual revenue | $14,400,000 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $46,000,000 |
| Total funding | $65,000,000 |
Key Contacts at ISTA Pharmaceuticals (Products now under Bausch + Lomb, which was acquired by Valeant)
Fen Liu
Director, Clinical Project Management
Brent Jones
Director Of Sales - Southeast
Dave Tobey
Director, Strategic Accounts
Sylvia Price
Financial Director
Maha Malih
Director
Jasbir Dhanjal
Director, Manufacturing
Joe Schiel
Sales Director
Kübra Nergiz
Owner
Wayne Caulder
Director
Maryam Aslam
Corporate Director
Company overview
| Headquarters | 50 Technology Drive, Irvine, CA 92618, US |
| Website | |
| NAICS | 3254 |
| Keywords | Ophthalmology And Niche Pharmaceutical |
| Founded | 2000 |
| Employees | 101-200 |
| Socials |
ISTA Pharmaceuticals (Products now under Bausch + Lomb, which was acquired by Valeant) Email Formats
ISTA Pharmaceuticals (Products now under Bausch + Lomb, which was acquired by Valeant) uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@bausch.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@bausch.com | 66.7% |
{first name}.{last name} | john.doe@bausch.com | 33.3% |
About ISTA Pharmaceuticals (Products now under Bausch + Lomb, which was acquired by Valeant)
ISTA Pharmaceuticals, Inc, was a rapidly growing specialty pharmaceutical company developing, marketing and selling products in the U.S. and Puerto Rico. It was the fourth largest branded prescription eye care business in the U.S. and had an emerging allergy drug franchise. Its products treated ocular inflammation and pain, glaucoma, dry eye and ocular allergies. It had a U.S. sales force of more than 165 representatives calling on ophthalmologists, optometrists and allergists. The four key products included: • BROMDAY™ (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extractions • BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% for the treatment of ocular itching associated with allergic conjunctivitis • ISTALOL® (timolol maleate ophthalmic solution) 0.05% for the treatment of glaucoma • VITRASE® (hyaluronidase injection) ovine, 200 USP units/ml for use as a spreading agent In June of 2012, ISTA was acquired by Bausch + Lomb and now operates under the Pharmaceutical business of Bausch + Lomb. In July of 2013, Bausch + Lomb was acquired by Valeant.
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
ISTA Pharmaceuticals (Products now under Bausch + Lomb, which was acquired by Valeant) has 85 employees across 10 departments.
Departments
Number of employees
Funding Data
Explore ISTA Pharmaceuticals (Products now under Bausch + Lomb, which was acquired by Valeant)'s funding history, including investment rounds, total capital raised, and key backers.
Italy
Canada
Finland
United KingdomFrequently asked questions
4.8
40,000 users
